1
|
Proffer SL, Reinhart JP, Campbell EH, Crum OM, Gibson LE, Brewer JD, Demer AM. Increasing Incidence and Decreasing Mortality of Melanoma in Elderly Adults: An Epidemiologic Study in Olmsted County, Minnesota. Dermatol Surg 2024; 50:125-130. [PMID: 37792642 DOI: 10.1097/dss.0000000000003972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023]
Abstract
BACKGROUND AND OBJECTIVE Primary cutaneous melanoma incidence is increasing in elderly individuals. This population-based cohort examines incidence and mortality rates among adults aged 61 years and older with cutaneous melanoma. MATERIALS AND METHODS Using the Rochester Epidemiology Project, patients aged 61 years of age or older with a first lifetime diagnosis of cutaneous melanoma between January 1, 1970 and December 31, 2020 were identified. RESULTS The age- and sex-adjusted incidence rate increased from 16.4 (95% CI, 8.2-24.6) per 100,000 person-years in 1970 to 1979 to 201.5 (95% CI, 185.1-217.8) per 100,000 person-years in 2011 to 2020 (12.3-fold increase). There was a 16.0x increase in males and an 8.5× increase in females. Melanoma incidence has stabilized in males (1.2-fold increase, p = .11) and continues to significantly increase in females (2.7-fold increase, p < .001). Older age at diagnosis was significantly associated with an increased risk of death (HR 1.23 per 5-year increase in age at diagnosis, 95% CI, 1.02-1.47). CONCLUSION Melanoma incidence continues to increase since 1970. The incidence has risen in elderly females, but has stabilized in males. Mortality has decreased throughout this period.
Collapse
Affiliation(s)
- Sydney L Proffer
- Department of Dermatology, Mayo Clinic School of Graduate Medical Education, Rochester, Minnesota
| | - Jacob P Reinhart
- Department of Dermatology, Mayo Clinic School of Graduate Medical Education, Rochester, Minnesota
| | - Elliott H Campbell
- Department of Dermatology, Mayo Clinic School of Graduate Medical Education, Rochester, Minnesota
| | - Olivia M Crum
- Department of Dermatology, Mayo Clinic School of Graduate Medical Education, Rochester, Minnesota
| | - Lawrence E Gibson
- Department of Dermatology, Division of Dermatopathology, Mayo Clinic, Rochester, Minnesota
| | - Jerry D Brewer
- Department of Dermatology, Division of Dermatologic Surgery, Mayo Clinic, Rochester, Minnesota
| | - Addison M Demer
- Department of Dermatology, Division of Dermatologic Surgery, Mayo Clinic, Rochester, Minnesota
| |
Collapse
|
2
|
Piasek AM, Musolf P, Sobiepanek A. Aptamer-based Advances in Skin Cancer Research. Curr Med Chem 2023; 30:953-973. [PMID: 35400317 DOI: 10.2174/0929867329666220408112735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Revised: 01/24/2022] [Accepted: 02/07/2022] [Indexed: 11/22/2022]
Abstract
Cancer diseases have been one of the biggest health threats for the last two decades. Approximately 9% of all diagnosed cancers are skin cancers, including melanoma and non-melanoma. In all cancer cases, early diagnosis is essential to achieve efficient treatment. New solutions and advanced techniques for rapid diagnosis are constantly being sought. Aptamers are single-stranded RNA or DNA synthetic sequences or peptides, which offer novel possibilities to this area of research by specifically binding selected molecules, the so-called cancer biomarkers. Nowadays, they are widely used as diagnostic probes in imaging and targeted therapy. In this review, we have summarized the recently made advances in diagnostics and treatment of skin cancers, which have been achieved by combining aptamers with basic or modern technologies.
Collapse
Affiliation(s)
- Adrianna Maria Piasek
- Laboratory of Biomolecular Interactions Studies, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland
| | - Paulina Musolf
- Laboratory of Biomolecular Interactions Studies, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland
| | - Anna Sobiepanek
- Laboratory of Biomolecular Interactions Studies, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland
| |
Collapse
|
3
|
Spaccarelli N, Drozdowski R, Peters MS, Grant-Kels JM. Dysplastic nevus part II: Dysplastic nevi: Molecular/genetic profiles and management. J Am Acad Dermatol 2023; 88:13-20. [PMID: 36252690 DOI: 10.1016/j.jaad.2022.05.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/29/2022] [Accepted: 05/02/2022] [Indexed: 11/21/2022]
Abstract
Dermatologists frequently see patients with clinically atypical nevi and dermatopathologists interpret histologically dysplastic nevi on a near-daily basis, but there is great variability in the definition and management of such lesions. This part of the CME review focuses on information published since the previous comprehensive review (2012), with emphasis on molecular and genetic attributes of histologically dysplastic nevi and clinical management.
Collapse
Affiliation(s)
- Natalie Spaccarelli
- Department of Dermatology, The Ohio State University Wexner Medical Center, Columubs, Ohio
| | - Roman Drozdowski
- University of Connecticut School of Medicine, Farmington, Connecticut
| | - Margot S Peters
- Departments of Dermatology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | - Jane M Grant-Kels
- Departments of Dermatology, Pathology and Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut; Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida.
| |
Collapse
|
4
|
Dziankowska-Zaborszczyk E, Maniecka-Bryła I, Pikala M. Mortality Trends Due to Skin Melanoma in Poland in the Years 2000-2020. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:16118. [PMID: 36498192 PMCID: PMC9739595 DOI: 10.3390/ijerph192316118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Revised: 11/20/2022] [Accepted: 11/29/2022] [Indexed: 06/17/2023]
Abstract
The aim of this article is to assess mortality trends due to skin melanoma in Poland between the years 2000 and 2020, taking into account gender and place of residence (urban, rural). The subject of the analyses was data on 25,061 deaths that occurred between 2000 and 2020 due to skin melanoma (C43 according to ICD-10). Mortality rates due to this cancer, both crude (CDR) and standardised (SDR), were calculated. Trends on the calculated rates were analysed using the annual percentage change (APC) and average annual percentage change (AAPC), obtained from joinpoint regression models. Over the study period, the standardised death rate (SDR) due to skin melanoma in Poland increased from 3.60 to 4.03 per 100,000 population (AAPC = 1.1; p < 0.05), for urban residents it increased from 3.56 to 3.91 (APC = 1.2; p < 0.05) and for rural residents it increased from 3.00 to 4.24 (APC = 2.2; p < 0.05). A higher growth rate in terms of the SDR value between the years 2000 and 2020 was recorded in men compared to women and in rural when compared to urban residents. In Poland, mortality due to skin melanoma is on the rise. The early diagnosis of this cancer should become common practice in the Polish population.
Collapse
|
5
|
Garcia-Ruiz A, Kornacker K, Brash DE. Cyclobutane Pyrimidine Dimer Hyperhotspots as Sensitive Indicators of Keratinocyte UV Exposure †. Photochem Photobiol 2022; 98:987-997. [PMID: 35944237 PMCID: PMC9802031 DOI: 10.1111/php.13683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Accepted: 07/25/2022] [Indexed: 01/03/2023]
Abstract
The dominant DNA damage generated by UV exposure is the cyclobutane pyrimidine dimer (CPD), which alters skin cell physiology and induces cell death and mutation. Genome-wide nucleotide-resolution analysis of CPDs in melanocytes and fibroblasts has identified "CPD hyperhotspots", pyrimidine-pyrimidine sites hundreds of fold more susceptible to the generation of CPDs than the genomic average. Identifying hyperhotspots in keratinocytes could enable measuring individual past UV exposure in small skin samples and predicting future skin cancer risk. We therefore exposed neonatal human epidermal keratinocytes to narrowband UVB and quantified CPDs using the adductSeq high-throughput DNA sequencing method. Keratinocytes contained thousands of CPD hyperhotspots, with a UVB-sensitivity up to 550 fold greater than the genomic average. As with melanocytes, the most sensitive sites were located in promoter regions at ETS-family transcription factor binding sequence motifs, near RNA processing genes. Moreover, they lay at sequence motifs bound to ETS1 in CpG islands. These genes were specifically upregulated in skin and the CPD hyperhotspots were mutated in a fraction of keratinocyte cancers. Crucially for their biological importance and practical application, CPD hyperhotspot locations and UV-sensitivity ranking demonstrated high reproducibility across experiments and across skin donors. CPD hyperhotspots are therefore sensitive indicators of UV exposure.
Collapse
Affiliation(s)
- Alejandro Garcia-Ruiz
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, USA
| | | | - Douglas E. Brash
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, USA
- Department of Dermatology, Yale School of Medicine, New Haven, CT 06520-8059, USA
- Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520-8028, USA
| |
Collapse
|
6
|
Merten JW, Hamadi HY, King JL. Cancer Risk Perceptions Among People Who Check Their Skin for Skin Cancer: Results from the 2017 U.S. Health Information National Trends Survey (HINTS). JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2022; 37:770-778. [PMID: 32968953 DOI: 10.1007/s13187-020-01880-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 09/16/2020] [Indexed: 06/11/2023]
Abstract
When detected early, melanoma is highly treatable and rarely fatal. Self-skin checks can identify changes in moles that could be an indicator of melanoma. Cancer risk perceptions may influence the uptake of important preventive health behaviors such as self-skin checks. The purpose of this study is to examine cancer risk perception factors associated with those who have checked their skin for signs of skin cancer using the 2017 HINTS data. Retrospective cross-sectional analysis of a nationally representative sample of U.S. adults using the Health Information National Trends Survey (HINTS). Logistic regressions were performed to identify associations between having checked skin for signs of skin cancer, risk perceptions, and demographic variables. White women over the age of 45 with a college degree and annual incomes greater than $75,000 were more likely to check their skin for signs of skin cancer. More than a third reported they would rather not know if they had cancer and more than 60% had some level of worry about having cancer. Those with a personal or family history of cancer were more likely to check. HINTS is a cross-sectional survey which provides only a glimpse of behavioral predictors. Self-skin checks are simple and cost-effective to detect melanoma early and improve outcomes. Fear and worry about cancer were significant factors in the likelihood of checking skin for signs of skin cancer. Population-based strategies could be developed to reduce concerns about early detection.
Collapse
Affiliation(s)
- Julie Williams Merten
- Department of Public Health, Brooks College of Health, University of North Florida, 1 UNF Drive, Jacksonville, FL, 32224, USA.
| | - Hanadi Y Hamadi
- Department of Health Administration, University of North Florida, Jacksonville, FL, USA
| | - Jessica L King
- Department of Health and Kinesiology, University of Utah, Salt Lake City, UT, USA
| |
Collapse
|
7
|
Sobiepanek A, Milner-Krawczyk M, Musolf P, Starecki T, Kobiela T. Anandamide-Modulated Changes in Metabolism, Glycosylation Profile and Migration of Metastatic Melanoma Cells. Cancers (Basel) 2022; 14:cancers14061419. [PMID: 35326572 PMCID: PMC8946642 DOI: 10.3390/cancers14061419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 03/05/2022] [Accepted: 03/08/2022] [Indexed: 12/10/2022] Open
Abstract
Simple Summary Anandamide (AEA) belongs to the group of endocannabinoids and possesses various regulatory properties in physiological as well as pathological processes occurring in the organism. In this research some basic biological tests were applied to investigate AEA-induced changes in cell metabolism and motility, as well as advanced biophysical methods for the determination of the differences in the cell glycosylation profile on a highly dangerous model of melanoma skin cancer, for which an effective therapy is not yet available. Our research suggests that anandamide treatment of metastatic melanoma cells increases the cell metabolism which leads to the reduction in the metastatic potential of cells in terms of the cell glycosylation profile and cell migration. In the view of our research, it can be presumed that anandamide usage in the combined therapy of advanced melanoma would be an advantage for the patient. Abstract An effective therapy for advanced melanoma, a skin cancer with the highest mortality, has not yet been developed. The endocannabinoid system is considered to be an attractive target for cancer treatment. The use of endocannabinoids, such as anandamide (AEA), is considered to be much greater than as a palliative agent. Thus, we checked its influence on various signaling pathways in melanoma cells. Our investigation was performed on four commercial cell lines derived from different progression stages (radial WM35 and vertical WM115 growth phases, lymph node WM266-4 metastasis, solid tumor A375-P metastasis). Cell viability, glucose uptake, quantification of reactive oxygen species production, expression of selected genes encoding glycosyltransferases, quantification of glycoproteins production and changes in the glycosylation profile and migration, as well as in cell elastic properties were analyzed. The cell glycosylation profile was investigated using the biophysical profiling method—the quartz crystal microbalance with dissipation monitoring (QCM-D). Anandamide treatment of only metastatic cells resulted in: an increase in the cell metabolism, a decrease in GFAT-1 and DPM1 expression, followed by a decrease in L1-CAM glycoprotein production, which further influenced the reduction in the cell glycosylation profile and migration. Considering our results, AEA usage is highly recommended in the combined therapy of advanced melanoma.
Collapse
Affiliation(s)
- Anna Sobiepanek
- Laboratory of Biomolecular Interactions Studies, Chair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-662 Warsaw, Poland; (M.M.-K.); (P.M.)
- Correspondence: (A.S.); (T.K.); Tel.: +48-792-350-130 (A.S.); +48-880-010-863 (T.K.)
| | - Małgorzata Milner-Krawczyk
- Laboratory of Biomolecular Interactions Studies, Chair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-662 Warsaw, Poland; (M.M.-K.); (P.M.)
| | - Paulina Musolf
- Laboratory of Biomolecular Interactions Studies, Chair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-662 Warsaw, Poland; (M.M.-K.); (P.M.)
| | - Tomasz Starecki
- Institute of Electronic Systems, Warsaw University of Technology, Nowowiejska 15/19, 00-665 Warsaw, Poland;
| | - Tomasz Kobiela
- Laboratory of Biomolecular Interactions Studies, Chair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-662 Warsaw, Poland; (M.M.-K.); (P.M.)
- Correspondence: (A.S.); (T.K.); Tel.: +48-792-350-130 (A.S.); +48-880-010-863 (T.K.)
| |
Collapse
|
8
|
Sobiepanek A, Kowalska PD, Szota M, Grzywa TM, Nowak J, Włodarski PK, Galus R, Jachimska B, Kobiela T. Novel diagnostic and prognostic factors for the advanced melanoma based on the glycosylation-related changes studied by biophysical profiling methods. Biosens Bioelectron 2022; 203:114046. [PMID: 35121451 DOI: 10.1016/j.bios.2022.114046] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 01/21/2022] [Accepted: 01/25/2022] [Indexed: 12/28/2022]
Abstract
Melanoma is a life-threatening disease due to the early onset of metastasis and frequent resistance to the applied treatment. For now, no single histological, immunohistochemical or serological biomarker was able to provide a precise predictive value for the aggressive behavior in melanoma patients. Thus, the search for quantifying methods allowing a simultaneous diagnosis and prognosis of melanoma patients is highly desirable. By investigating specific molecular interactions with some biosensor-based techniques, one can determine novel prognostic factors for this tumor. In our previous study, we have shown the possibility of a qualitative in vitro distinguishing the commercially available melanoma cells at different progression stages based on the measurements of the lectin Concanavalin A interacting with surface glycans present on cells. Here, we present the results of the quantitative diagnostic and prognostic study of both commercial and patient-derived melanoma cells based on the evaluation of two novel factors: lectin affinity and glycan viscoelastic index obtained from the quartz crystal microbalance with dissipation monitoring (QCM-D) measurements. Two approaches to the QCM-D measurements were applied, the first uses the ability of melanoma cells to grow as a monolayer of cells on the sensor (cell-based sensors), and the second shortens the time of the analysis (suspension cell based-sensors). The results were confirmed by the complementary label-free (atomic force microscopy, AFM; and surface plasmon resonance, SPR) and labeling (lectin-ELISA; and microscale thermophoresis, MST) techniques. This new approach provides additional quantitative diagnosis and a personalized prognosis which can be done simultaneously to the traditional histopathological analysis.
Collapse
Affiliation(s)
- Anna Sobiepanek
- Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.
| | - Patrycja D Kowalska
- Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland; Polish Stem Cell Bank, Warsaw, Poland
| | - Magdalena Szota
- Jerzy Haber Institute of Catalysis and Surface Chemistry Polish Academy of Sciences, Krakow, Poland
| | - Tomasz M Grzywa
- Department of Methodology, Centre for Preclinical Research, Medical University of Warsaw, Poland; Department of Immunology, Medical University of Warsaw, Warsaw, Poland; Doctoral School, Medical University of Warsaw, Warsaw, Poland
| | - Jakub Nowak
- Department of Physical Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
| | - Paweł K Włodarski
- Department of Methodology, Centre for Preclinical Research, Medical University of Warsaw, Poland
| | - Ryszard Galus
- Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland
| | - Barbara Jachimska
- Jerzy Haber Institute of Catalysis and Surface Chemistry Polish Academy of Sciences, Krakow, Poland
| | - Tomasz Kobiela
- Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.
| |
Collapse
|
9
|
Investigation of skin self-examination and sunscreen use in adolescents in northern Cyprus. Postepy Dermatol Alergol 2021; 38:505-509. [PMID: 34377135 PMCID: PMC8330876 DOI: 10.5114/ada.2021.107937] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Accepted: 08/17/2020] [Indexed: 01/22/2023] Open
Abstract
Introduction Regular skin self-examination (SSE) is very important for the early diagnosis of malignant melanoma (MM). Since sun exposure is the most important trigger factor for the development of skin cancers, effective and regular sun protection is the main preventive method. Aim To investigate the awareness of SSE, risky nevus and sun protection of the adolescents in the Turkish Republic of Northern Cyprus (TRNC). Material and methods The data used within this research were obtained from questionnaires administered to volunteer high school students in the TRNC. Results 39.8% of the participants included in the study stated that they conducted SSE. All the participants who said they conducted SSE reported that they performed a face exam. The body regions that the participants did not examine were the scalp (47.7%), foot (36.9%), back (35.4%) and genital area (35.4%). The features of the nevus perceived by the participants as risk factors included rapid growth, bleeding and itching. While 74% of respondents said they used sunscreen products, only 9% of users reported using them every day. Conclusions In the TRNC where the exposure to the sun is high, young people perform skin examinations at high rates in order to monitor their nevi. Nevertheless, the results of this research show that hard-to-reach areas are neglected.
Collapse
|
10
|
Kennedy C, Liu Y, Meng X, Strosnider H, Waller LA, Zhou Y. Developing indices to identify hotspots of skin cancer vulnerability among the Non-Hispanic White population in the United States. Ann Epidemiol 2021; 59:64-71. [PMID: 33895246 DOI: 10.1016/j.annepidem.2021.04.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 04/09/2021] [Accepted: 04/09/2021] [Indexed: 11/26/2022]
Abstract
PURPOSE Skin cancer is the most common, yet oftentimes preventable, cancer type in the United States. Exposure to ultraviolet radiation from sunlight is the most prominent environmental risk factor for skin cancer. Besides environmental exposure, demographic characteristics such as race, age, and socioeconomic status may make some groups more vulnerable. An exploratory spatial clustering method is described for identifying clusters of vulnerability to skin cancer incidence and mortality based on composite indices, which combine data from environmental and demographic risk factors. METHODS Based on county-level ultraviolet data and demographic risk factors, two vulnerability indices for skin cancer were generated using an additive percentile rank approach. With these indices, univariate local Moran's I spatial autocorrelation identified significant clusters, or hotspots, of neighboring counties with high overall vulnerability indices. Clusters were identified separately for skin cancer incidence and mortality. RESULTS Counties with high vulnerabilities were spatially distributed across the United States in a pattern that generally increased to the South and West. Clusters of counties with high skin cancer incidence vulnerability were mostly observed in Utah and Colorado, even with highly conservative levels of significance. Meanwhile, clusters for skin cancer mortality vulnerability were observed in southern Alabama and west Florida as well as across north Alabama, north Georgia and up through the Tennessee-North Carolina area. CONCLUSIONS Future skin cancer research and screening initiatives may use these innovative composite vulnerability indices and identified clusters to better target resources based on anticipated risk from underlying demographic and environmental factors.
Collapse
Affiliation(s)
- Caitlin Kennedy
- Environmental Health Tracking Section, Division of Environmental Health Practice and Science, National Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC), Atlanta, GA
| | - Yang Liu
- Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA
| | - Xia Meng
- School of Public Health, Fudan University, Shanghai, China
| | - Heather Strosnider
- Environmental Health Tracking Section, Division of Environmental Health Practice and Science, National Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC), Atlanta, GA
| | - Lance A Waller
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA
| | - Ying Zhou
- Environmental Health Tracking Section, Division of Environmental Health Practice and Science, National Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC), Atlanta, GA.
| |
Collapse
|
11
|
Kaufmann C, Kempf W, Mangana J, Cheng P, Emberger M, Lang R, Kaiser AK, Lattmann E, Levesque M, Dummer R, Koelblinger P. The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma. Histopathology 2020; 77:460-470. [PMID: 32374893 PMCID: PMC7540531 DOI: 10.1111/his.14139] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Accepted: 05/03/2020] [Indexed: 12/16/2022]
Abstract
AIMS Despite their low individual metastatic potential, thin melanomas (≤1 mm Breslow thickness) contribute significantly to melanoma mortality overall. Therefore, identification of prognostic biomarkers is particularly important in this subgroup of melanoma. Prompted by preclinical results, we investigated cyclin D1 protein and Ki-67 expression in in-situ, metastatic and non-metastatic thin melanomas. METHODS AND RESULTS Immunohistochemistry was performed on 112 melanoma specimens, comprising 22 in situ, 48 non-metastatic and 42 metastatic thin melanomas. Overall, epidermal and dermal cyclin D1 and Ki-67 expression were semiquantitatively evaluated by three independent investigators and compared between groups. Epidermal Ki-67 expression did not differ statistically in in-situ and invasive melanoma (P = 0.7). Epidermal cyclin D1 expression was significantly higher in thin invasive than in in-situ melanoma (P = 0.003). No difference was found in cyclin D1 expression between metastatic and non-metastatic invasive tumours. Metastatic and non-metastatic thin melanomas did not show significant differences in epidermal expression of Ki-67 and cyclin D1 (P = 0.148 and P = 0.611, respectively). In contrast, strong dermal expression of Ki-67 was more frequent in metastatic than non-metastatic samples (28.6 versus 8.3%, respectively, P = 0.001). The prognostic value of dermal Ki-67 expression was confirmed by multivariate analysis (P = 0.047). CONCLUSION We found an increased expression of cyclin D1 in invasive thin melanomas compared to in-situ melanomas, which supports a potential role of this protein in early invasion in melanoma, as suggested by preclinical findings. Moreover, our results confirm that high dermal Ki-67 expression is associated with an increased risk of development of metastasis in thin melanoma and could possibly serve as a prognostic biomarker in clinical practice, especially if combined with additional methods.
Collapse
Affiliation(s)
- Corina Kaufmann
- Department of DermatologyUniversity Hospital ZurichZurichSwitzerland
- University of ZurichZurichSwitzerland
| | - Werner Kempf
- Kempf and Pfaltz Histological DiagnosticsZurichSwitzerland
| | - Joanna Mangana
- Department of DermatologyUniversity Hospital ZurichZurichSwitzerland
| | - Phil Cheng
- Department of DermatologyUniversity Hospital ZurichZurichSwitzerland
| | | | - Roland Lang
- Department of Dermatology and AllergologyParacelsus Medical UniversitySalzburgAustria
| | - Andreas K Kaiser
- Department of Clinical PsychologyChristian‐Doppler‐KlinikParacelsus Medical UniversitySalzburgAustria
| | | | - Mitchell Levesque
- Department of DermatologyUniversity Hospital ZurichZurichSwitzerland
| | - Reinhard Dummer
- Department of DermatologyUniversity Hospital ZurichZurichSwitzerland
| | - Peter Koelblinger
- Department of DermatologyUniversity Hospital ZurichZurichSwitzerland
- Department of Dermatology and AllergologyParacelsus Medical UniversitySalzburgAustria
| |
Collapse
|
12
|
Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years. Melanoma Res 2019; 28:629-636. [PMID: 30204684 DOI: 10.1097/cmr.0000000000000511] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The current research aimed to understand melanoma epidemiology in Brazil and to evaluate temporal trends in incidence and mortality. The data came from Brazilian Hospital Cancer Registries, Population Based Cancer Registries, and the National Mortality Information System from 2000 to 2014. Descriptive statistics were used for epidemiological and clinical characteristics. To describe trends in change in incidence and mortality rates, the Average Annual Percentage Change (AAPC) was calculated. Between 2000 and 2013, in men, the median incidence rate rose from 2.52 to 4.84, with an AAPC of +21.5% [95% confidence interval (CI): 15.4-28] and in women from 1.93 to 3.22 per 100 000, with an AAPC of +13.9% (95% CI: 8.1-20). Regarding mortality, between 2000 and 2014, the rates went from 0.85 to 0.9 per 100 000 for men (AAPC=+0.8, 95% CI: 0.4-1.1) and from 0.56 for 0.53 per 100 000 for women (AAPC=-0.1, 95% CI: -0.2 to 0). From the database, a total of 28 624 patients with melanoma were included. Most of the patients were females (51.9%), White (75%) and with stage I or II (53.2%). Sex, ethnicity, education level, geographical area of the cancer center, topography, histology, time between diagnosis and treatment, and early death were significantly associated with distant metastases. Brazil is a large country with a very young population and a low rate of melanoma incidence and prevalence that should increase over the years. Understanding the trends attributed to melanoma is important for behavioral counseling interventions that focus on promoting skin cancer prevention.
Collapse
|
13
|
Malignant melanoma clinically mimicking pyogenic granuloma: comparison of clinical evaluation and histopathology. Melanoma Res 2019; 28:363-367. [PMID: 29750750 DOI: 10.1097/cmr.0000000000000451] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Amelanotic melanomas (AMMs) account for a small proportion of all melanomas. They pose a risk of delayed diagnosis and, consequently, poor prognosis. AMMs may atypically present as a pyogenic granuloma-like lesion. This study sought to investigate the prevalence and clinical and histological features of AMM masquerading as pyogenic granuloma. The database of a tertiary medical center was screened for all patients pathologically diagnosed with melanoma in 2005-2016. Those with a suspected primary (i.e. pre-excision) clinical diagnosis of pyogenic granuloma were identified, and their demographic, clinical, histologic, and outcome data were collected from the medical files. Of 2038 patients diagnosed with melanoma, 10 (∼0.5%) had a pyogenic granuloma-like AMM. The mean±SD age at lesion presentation was 56±18.9 years and the mean time from lesion appearance to diagnosis was 91.5±117.1 months. Nine tumors were located on the skin surface, and one on the oral mucosa. The mean lesion size was 19.6±14.1 mm and the mean Breslow's depth was 6.47±3.1 mm; all tumors presented in the vertical growth phase. Seven (70%) patients had lymph node involvement or metastasis at diagnosis. Two patients died of the disease within 1 year of diagnosis. Given the potential lethality of AMM and the benign nature of pyogenic granuloma, clinician recognition of pyogenic granuloma-like AMMs is crucial. In the presence of a pyogenic granuloma-like lesion, findings of older patient age and large tumor size should raise the index of suspicion and prompt a biopsy study, thereby ensuring early and accurate treatment.
Collapse
|
14
|
Risk factors for development of new skin neoplasms in patients with past history of skin cancer: A survival analysis. Sci Rep 2018; 8:15744. [PMID: 30356134 PMCID: PMC6200724 DOI: 10.1038/s41598-018-33763-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Accepted: 09/27/2018] [Indexed: 11/08/2022] Open
Abstract
We conducted a retrospective study aiming to assess the risk, and associated risk factors, of developing subsequent skin cancers after having a first diagnosis of skin cancer. We included all patients with biopsy-proven skin cancer attending a dermatology clinic between July 2007 and July 2017. We assessed the frequency of new skin cancers, as well as potential demographic and clinical factors significantly associated with occurrence of such neoplasms, that were identified by means of a survival analysis. We analyzed 969 patients with a total of 1584 skin neoplasms (1122 basal cell carcinomas (BCC), 310 squamous cell carcinomas (SCC), 143 melanomas and 9 other neoplasms). 165 patients (17.0%) developed subsequent skin neoplasms. Factors identified in multivariable models to be significantly associated with development of new skin cancers included older age (adjusted HR = 1.04 per year; 95%CI = 1.02-1.05; p < 0.001), and presence of synchronous neoplasms (adjusted HR = 2.25; 95%CI = 1.61-3.14; p < 0.001). Having a history of a BCC was significantly associated with development of new BCC (adjusted HR = 1.63; 95%CI = 1.05-2.54; p = 0.030), while having a previous SCC was associated with occurrence of subsequent SCC (adjusted HR = 3.60; 95%CI = 1.93-6.72; p < 0.001). These findings point to the importance of careful follow-up (e.g., skin self-examination and full body examination) of skin cancer patients.
Collapse
|
15
|
Marek AJ, Chu EY, Ming ME, Khan ZA, Kovarik CL. Piloting the Use of Smartphones, Reminders, and Accountability Partners to Promote Skin Self-Examinations in Patients with Total Body Photography: A Randomized Controlled Trial. Am J Clin Dermatol 2018; 19:779-785. [PMID: 30062632 DOI: 10.1007/s40257-018-0372-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE The aim of this study was to evaluate the use of a mobile application (app) in patients already using total body photography (TBP) to increase skin self-examination (SSE) rates and pilot the effectiveness of examination reminders and accountability partners. DESIGN Randomized controlled trial with computer generated randomization table to allocate interventions. SETTING University of Pennsylvania pigmented lesion clinic. PARTICIPANTS 69 patients aged 18 years or older with an iPhone/iPad, who were already in possession of TBP photographs. INTERVENTION A mobile app loaded with digital TBP photos for all participants, and either (1) the mobile app only, (2) skin examination reminders, (3) an accountability partner, or (4) reminders and an accountability partner. MAIN OUTCOME MEASURE Change in SSE rates as assessed by enrollment and end-of-study surveys 6 months later. RESULTS Eighty one patients completed informed consent, however 12 patients did not complete trial enrollment procedures due to device incompatibility, leaving 69 patients who were randomized and analyzed [mean age 54.3 years, standard deviation 13.9). SSE rates increased significantly from 58% at baseline to 83% at 6 months (odds ratio 2.64, 95% confidence interval 1.20-4.09), with no difference among the intervention groups. The group with examination reminders alone had the highest (94%) overall satisfaction, and the group with accountability partners alone accounted for the lowest (71%). CONCLUSION A mobile app alone, or with reminders and/or accountability partners, was found to be an effective tool that can help to increase SSE rates. Skin examination reminders may help provide a better overall experience for a subset of patients. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02520622.
Collapse
Affiliation(s)
- Andrew J Marek
- Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
- Department of Medicine, MedStar Harbor Hospital, Baltimore, MD, USA.
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
| | - Emily Y Chu
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Michael E Ming
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Zeeshan A Khan
- Department of Medicine, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA
| | - Carrie L Kovarik
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
16
|
Steglich RB, Coelho KMDPA, Cardoso S, Gaertner MHDCN, Cestari TF, Franco SC. Epidemiological and histopathological aspects of primary cutaneous melanoma in residents of Joinville, 2003-2014. An Bras Dermatol 2018; 93:45-53. [PMID: 29641696 PMCID: PMC5871361 DOI: 10.1590/abd1806-4841.20185497] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Accepted: 10/06/2016] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND The worldwide incidence of cutaneous melanoma (CM) has been continuously increasing over the last decades. Primary and secondary prevention, with attention to risk factors and early diagnosis, remain the cornerstone for reducing the burden of cutaneous melanoma. Detailed information with respect to clinical and pathological data on cutaneous melanoma is scarce in Brazil. OBJECTIVE The purpose of our study was to analyze epidemiological and pathological characteristics of primary cutaneous melanoma in Joinville, southern Brazil. METHODS Observational, cross-sectional, retrospective study in which 893 reports of primary cutaneous melanoma from the local population were analyzed in the period 2003-2014. The study was approved by the local Ethics and Research Committee. RESULTS We observed a female predominance of cutaneous melanoma (56.3%). The age standardized incidence rate of primary cutaneous melanoma for the world population in the period 2003-06 was 11.8 per 100,000 population (CI 95%, 10.3-13.4), and 17.5 (CI 95%, 15.7-19.3) in 2011-14, revealing a significant increase of 48.3% (p < 0,05). Six and a half percent of patients had multiple cutaneous melanomas (mean 2.2 years and a maximum of 10.0 years between diagnoses). We observed significant differences between the location head/neck and cutaneous melanoma in situ, lower limb with Breslow depth S III and upper limb with Breslow depth S I. The comparison of the characteristics of cutaneous melanoma in the elderly and non-elderly (< 60 years old) showed significant differences with respect to all the variables studied. STUDY LIMITATIONS Using secondary data source. CONCLUSION Joinville has high incidence coefficients for Brazilian standards, showing an increase in the incidence of cutaneous melanoma.
Collapse
Affiliation(s)
| | | | - Silvana Cardoso
- Academy of the Universidade da Região de Joinville
(UNIVILLE) - Joinville (SC), Brazil
| | | | - Tania Ferreira Cestari
- Dermatology Service at Universidade Federal do Rio Grande do Sul
(UFRGS) - Porto Alegre (RS), Brazil
| | - Selma Cristina Franco
- Public Health Division of the Universidade da Região de
Joinville (UNIVILLE) - Joinville (SC), Brazil
| |
Collapse
|
17
|
Wojcik KY, Escobedo LA, Miller KA, Hawkins M, Ahadiat O, Higgins S, Wysong A, Cockburn M. Conflicts and Contradictions in Current Skin Cancer Screening Guidelines. CURRENT DERMATOLOGY REPORTS 2017; 6:316-324. [DOI: 10.1007/s13671-017-0205-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
18
|
Luo D, Deng B, Weng M, Luo Z, Nie X. A prognostic 4-lncRNA expression signature for lung squamous cell carcinoma. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2017; 46:1207-1214. [PMID: 28835135 DOI: 10.1080/21691401.2017.1366334] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The outcomes of Lung squamous cell carcinoma (LUSC) is still challenging to evaluate or predict. We aimed to screen prognostic lncRNAs and to mine their roles in LUSC. RNA-Seq data of primary lung cancer were extracted from the Cancer Genome Atlas. Generally, changed lncRNAs in cancer samples were screened and analyzed in univariate survival analysis for identification of prognostic lncRNAs. Robust likelihood-based survival model was generated and random sampling iterations were performed 1000 times to calculate the frequency of feature key lncRNAs. Clustering and multivariate survival analysis of these lncRNAs was used to evaluate their functions and impacts on prognosis. Finally, the stability and validity of the optimal clustering model were verified. In total, we obtained 5664 generally changed lncRNAs among primary lung cancer samples, including 289 identified relating to prognosis in univariate survival analysis. Robust likelihood-based survival modelling for 1000 iterations generated 11 feature lncRNAs with frequency larger than 300. Their interacting proteins were found participating in DNA repairing and cell proliferation. Among stable assembly of 11 lncRNAs, a 4-lncRNA model was selected finally with high stability and feasibility. The ideal 4-lncRNA model can cluster patient samples with significant difference, providing new avenues for the prognostic predication of LUSC.
Collapse
Affiliation(s)
- Danju Luo
- a Department of Pathology , Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , China
| | - Bin Deng
- b Intensive Care Unit , Zhongnan Hospital of Wuhan University , Wuhan , China
| | - Mixia Weng
- a Department of Pathology , Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , China
| | - Zhen Luo
- c Research Center for Tissue Engineering and Regenerative Medicine , Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , China
| | - Xiu Nie
- a Department of Pathology , Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , China
| |
Collapse
|
19
|
Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag 2017; 4:13-37. [PMID: 28758010 PMCID: PMC5480135 DOI: 10.2217/mmt-2016-0022] [Citation(s) in RCA: 77] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Accepted: 09/07/2016] [Indexed: 02/07/2023] Open
Abstract
Melanoma is usually apparent on the skin and readily detected by trained medical providers using a routine total body skin examination, yet this malignancy is responsible for the majority of skin cancer-related deaths. Currently, there is no national consensus on skin cancer screening in the USA, but dermatologists and primary care providers are routinely confronted with making the decision about when to recommend total body skin examinations and at what interval. The objectives of this paper are: to propose rational, risk-based, data-driven guidelines commensurate with the US Preventive Services Task Force screening guidelines for other disorders; to compare our proposed guidelines to recommendations made by other national and international organizations; and to review the US Preventive Services Task Force's 2016 Draft Recommendation Statement on skin cancer screening.
Collapse
Affiliation(s)
- Mariah M Johnson
- Department of Dermatology, Oregon Health & Science University, 3303 SW Bond Ave., Portland, OR, USA.,Department of Dermatology, Oregon Health & Science University, 3303 SW Bond Ave., Portland, OR, USA
| | - Sancy A Leachman
- Department of Dermatology, Oregon Health & Science University, 3303 SW Bond Ave., Portland, OR, USA.,Department of Dermatology, Oregon Health & Science University, 3303 SW Bond Ave., Portland, OR, USA
| | - Lisa G Aspinwall
- University of Utah, Salt Lake City, UT, USA.,University of Utah, Salt Lake City, UT, USA
| | - Lee D Cranmer
- University of Washington, Seattle, WA, USA.,University of Washington, Seattle, WA, USA
| | - Clara Curiel-Lewandrowski
- University of Arizona Cancer Center, Tucson, AZ, USA.,University of Arizona Cancer Center, Tucson, AZ, USA
| | - Vernon K Sondak
- Moffitt Cancer Center, Tampa, FL, USA.,Moffitt Cancer Center, Tampa, FL, USA
| | - Clara E Stemwedel
- Oregon Health & Science University, Portland, OR, USA.,Oregon Health & Science University, Portland, OR, USA
| | - Susan M Swetter
- Stanford University Medical Center & VA Palo Alto Health Care System, Palo Alto, CA, USA.,Stanford University Medical Center & VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - John Vetto
- Oregon Health & Science University, Portland, OR, USA.,Oregon Health & Science University, Portland, OR, USA
| | - Tawnya Bowles
- Intermountain Healthcare & University of Utah, Salt Lake City, UT, USA.,Intermountain Healthcare & University of Utah, Salt Lake City, UT, USA
| | - Robert P Dellavalle
- University of Colorado, Aurora, CO, USA.,University of Colorado, Aurora, CO, USA
| | - Larisa J Geskin
- Columbia University, New York, NY, USA.,Columbia University, New York, NY, USA
| | - Douglas Grossman
- University of Utah, Salt Lake City, UT, USA.,University of Utah, Salt Lake City, UT, USA
| | - Kenneth F Grossmann
- University of Utah, Salt Lake City, UT, USA.,University of Utah, Salt Lake City, UT, USA
| | - Jason E Hawkes
- University of Utah, Salt Lake City, UT, USA.,University of Utah, Salt Lake City, UT, USA
| | - Joanne M Jeter
- The Ohio State University, Columbus, OH, USA.,The Ohio State University, Columbus, OH, USA
| | - Caroline C Kim
- Harvard Medical School, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - John M Kirkwood
- University of Pittsburgh, Pittsburgh, PA, USA.,University of Pittsburgh, Pittsburgh, PA, USA
| | - Aaron R Mangold
- Mayo Clinic Arizona, Scottsdale, AZ, USA.,Mayo Clinic Arizona, Scottsdale, AZ, USA
| | - Frank Meyskens
- University of California, Irvine, Orange, CA, USA.,University of California, Irvine, Orange, CA, USA
| | - Michael E Ming
- University of Pennsylvania, Philadelphia, PA, USA.,University of Pennsylvania, Philadelphia, PA, USA
| | - Kelly C Nelson
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA.,The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michael Piepkorn
- University of Washington, Seattle, WA, USA.,University of Washington, Seattle, WA, USA
| | - Brian P Pollack
- Emory University & Atlanta VA Medical Center, Atlanta, GA, USA.,Emory University & Atlanta VA Medical Center, Atlanta, GA, USA
| | - June K Robinson
- Northwestern University Feinberg School of Medicine, Chicago, IL USA.,Northwestern University Feinberg School of Medicine, Chicago, IL USA
| | - Arthur J Sober
- Harvard Medical School, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Shannon Trotter
- The Ohio State University, Columbus, OH, USA.,The Ohio State University, Columbus, OH, USA
| | - Suraj S Venna
- Inova Medical Group, Fairfax, VA, USA.,Inova Medical Group, Fairfax, VA, USA
| | - Sanjiv Agarwala
- St Luke's University Hospital & Temple University, Bethlehem, PA, USA.,St Luke's University Hospital & Temple University, Bethlehem, PA, USA
| | - Rhoda Alani
- Boston University, Boston, MA, USA.,Boston University, Boston, MA, USA
| | - Bruce Averbook
- Case Western Reserve University, Cleveland, OH, USA.,Case Western Reserve University, Cleveland, OH, USA
| | - Anna Bar
- Oregon Health & Science University, Portland, OR, USA.,Oregon Health & Science University, Portland, OR, USA
| | - Mirna Becevic
- University of Missouri, Columbia, MO, USA.,University of Missouri, Columbia, MO, USA
| | - Neil Box
- University of Colorado, Aurora, CO, USA.,University of Colorado, Aurora, CO, USA
| | - William E Carson
- The Ohio State University, Columbus, OH, USA.,The Ohio State University, Columbus, OH, USA
| | - Pamela B Cassidy
- Oregon Health & Science University, Portland, OR, USA.,Oregon Health & Science University, Portland, OR, USA
| | - Suephy C Chen
- Emory University & Atlanta VA Medical Center, Atlanta, GA, USA.,Emory University & Atlanta VA Medical Center, Atlanta, GA, USA
| | - Emily Y Chu
- University of Pennsylvania, Philadelphia, PA, USA.,University of Pennsylvania, Philadelphia, PA, USA
| | - Darrel L Ellis
- Vanderbilt University, Nashville, TN, USA.,Vanderbilt University, Nashville, TN, USA
| | - Laura K Ferris
- University of Pittsburgh, Pittsburgh, PA, USA.,University of Pittsburgh, Pittsburgh, PA, USA
| | - David E Fisher
- Harvard Medical School & Massachusetts General Hospital, Charlestown, MA, USA.,Harvard Medical School & Massachusetts General Hospital, Charlestown, MA, USA
| | - Kari Kendra
- The Ohio State University, Columbus, OH, USA.,The Ohio State University, Columbus, OH, USA
| | - David H Lawson
- Winship Cancer Institute of Emory University, Atlanta, GA, USA.,Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - Philip D Leming
- The Christ Hospital, Cincinnati, OH, USA.,The Christ Hospital, Cincinnati, OH, USA
| | - Kim A Margolin
- City of Hope National Cancer Center, Duarte, CA, USA.,City of Hope National Cancer Center, Duarte, CA, USA
| | | | - Mary C Martini
- Northwestern University Feinberg School of Medicine, Chicago, IL USA.,Northwestern University Feinberg School of Medicine, Chicago, IL USA
| | - Debbie Miller
- Oregon Health & Science University, Portland, OR, USA.,Oregon Health & Science University, Portland, OR, USA
| | - Debjani Sahni
- Boston University, Boston, MA, USA.,Boston University, Boston, MA, USA
| | - William H Sharfman
- Johns Hopkins University, Baltimore, MD.,Johns Hopkins University, Baltimore, MD
| | - Jennifer Stein
- NYU Langone Medical Center, New York, NY, USA.,NYU Langone Medical Center, New York, NY, USA
| | - Alexander J Stratigos
- Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, Greece.,Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, Greece
| | - Ahmad Tarhini
- University of Pittsburgh, Pittsburgh, PA, USA.,University of Pittsburgh, Pittsburgh, PA, USA
| | - Matthew H Taylor
- Oregon Health & Science University, Portland, OR, USA.,Oregon Health & Science University, Portland, OR, USA
| | - Oliver J Wisco
- Bend Memorial Clinic, Bend, OR, USA.,Bend Memorial Clinic, Bend, OR, USA
| | - Michael K Wong
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.,University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
20
|
Al-Dujaili Z, Henry M, Dorizas AS, Sadick NS. Skin cancer concerns particular to women. Int J Womens Dermatol 2017; 3:S49-S51. [PMID: 28492039 PMCID: PMC5419056 DOI: 10.1016/j.ijwd.2017.02.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Revised: 07/16/2015] [Accepted: 07/16/2015] [Indexed: 12/28/2022] Open
Abstract
Background Skin cancer has reached epidemic proportions, with more new cases diagnosed annually than the combined incidence of cancers of the breast, prostate, lung, and colon. Estimates show 2 to 3 million new cases of non-melanoma skin cancer (NMSC) every year, and, among women, it is the young (younger than 45 years) who are disproportionately affected. Objective This article aims to address questions and concerns pertinent to skin cancer in a woman-centric way. An updated landscape of causative factors, the latest detection/treatment methods, and ultimately the preventative measures available to them are described. Methods A broad literature search was conducted using the PubMed database with search terms focusing on female gender. Additional articles were identified from cited references. Conclusions The published findings on causation of melanoma skin cancer and non-melanoma skin cancer in females are outlined, as well as current detection methods and treatment options. Furthermore, a variety of preventative measures specific to women that can reduce the chance of being diagnosed with skin cancer are discussed.
Collapse
Affiliation(s)
- Z Al-Dujaili
- Sadick Dermatology, New York, NY.,New York-Presbyterian Hospital, New York, NY
| | - M Henry
- Sadick Dermatology, New York, NY.,Department of Dermatology, Weill Cornell Medical College, New York, NY
| | - A S Dorizas
- Department of Dermatology, University at Buffalo, NY
| | - N S Sadick
- Sadick Dermatology, New York, NY.,Department of Dermatology, Weill Cornell Medical College, New York, NY
| |
Collapse
|
21
|
PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. Oncogene 2017; 36:3252-3262. [PMID: 28092671 DOI: 10.1038/onc.2016.469] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Revised: 10/12/2016] [Accepted: 10/31/2016] [Indexed: 12/19/2022]
Abstract
The cyclic AMP (cAMP) signaling pathway is critical in melanocyte biology for regulating differentiation. It is downregulated by phosphodiesterase (PDE) enzymes, which degrade cAMP itself. In melanoma evidence suggests that inhibition of the cAMP pathway by PDE type 4 (PDE4) favors tumor progression. For example, in melanomas harboring RAS mutations, the overexpression of PDE4 is crucial for MAPK pathway activation and proliferation induced by oncogenic RAS. Here we showed that PDE4D is overexpressed in BRAF-mutated melanoma cell lines, constitutively disrupting the cAMP pathway activation. PDE4D promoted melanoma invasion by interacting with focal adhesion kinase (FAK) through the scaffolding protein RACK1. Inhibition of PDE4 activity or inhibition of PDE4D interaction with FAK reduced invasion. PDE4D expression is increased in patients with advanced melanoma and PDE4D-FAK interaction is detectable in situ in metastatic melanoma. Our study establishes the role of PDE4D in BRAF-mutated melanoma as regulator of cell invasion, and suggests its potential as a target for preventing metastatic dissemination.
Collapse
|
22
|
|
23
|
Yang C, Cao H, Liu N, Xu K, Ding M, Mao LJ. Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma. DRUG DESIGN DEVELOPMENT AND THERAPY 2016; 10:3755-3761. [PMID: 27895465 PMCID: PMC5117872 DOI: 10.2147/dddt.s115121] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Conditionally replicating adenoviruses have emerged as novel therapeutic agents for cancer. This study aimed to evaluate synergistic antitumor activity of replication-competent adenovirus armed with interleukin (IL)-18 (ZD55-IL-18) and dacarbazine (DTIC) against melanoma. Melanoma A375 cells or nude mouse tumor xenografts were treated with ZD55-IL-18 alone or together with DTIC. The results showed that ZD55-IL-18 competently replicated in A375 cells and expressed IL-18, and these were not affected by DTIC. ZD55-IL-18 enhanced the cytotoxicity of DTIC accompanied by increased apoptosis. Moreover, ZD55-IL-18 and DTIC synergistically inhibited the growth but promoted the apoptosis of A375 xenografts and inhibited vascular endothelial growth factor expression and lung metastasis in xenografts of nude mice. In conclusion, this is the first study to show synergistic anticancer activity of ZD55-IL-18 and DTIC for malignant melanoma. Our results provide evidence that chemo-gene-viro therapeutic approach has greater potential for malignant cancers than conventional chemotherapy or gene therapy.
Collapse
Affiliation(s)
- Chunhua Yang
- Department of Urinary Surgery, The Affiliated Hospital of Xuzhou Medical University; Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, People's Republic of China
| | - Hang Cao
- Department of Urinary Surgery, The Affiliated Hospital of Xuzhou Medical University
| | - Ning Liu
- Department of Urinary Surgery, The Affiliated Hospital of Xuzhou Medical University
| | - Kai Xu
- Department of Urinary Surgery, The Affiliated Hospital of Xuzhou Medical University
| | - Meng Ding
- Department of Urinary Surgery, The Affiliated Hospital of Xuzhou Medical University
| | - Li-Jun Mao
- Department of Urinary Surgery, The Affiliated Hospital of Xuzhou Medical University
| |
Collapse
|
24
|
Prado G, D'Amore P, Tagliero A, Florez-White M, Acuna J. A cross-sectional study of trends in the stage of melanoma at diagnosis in the United States from 2001-2011. J Am Acad Dermatol 2016; 75:1057-1059. [PMID: 27745632 DOI: 10.1016/j.jaad.2016.07.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Revised: 07/05/2016] [Accepted: 07/13/2016] [Indexed: 11/26/2022]
Affiliation(s)
- Giselle Prado
- Herbert Wertheim College of Medicine, Florida International University, Miami, Florida.
| | - Peter D'Amore
- Herbert Wertheim College of Medicine, Florida International University, Miami, Florida
| | - Adam Tagliero
- Herbert Wertheim College of Medicine, Florida International University, Miami, Florida
| | - Mercedes Florez-White
- Herbert Wertheim College of Medicine, Florida International University, Miami, Florida
| | - Juan Acuna
- Herbert Wertheim College of Medicine, Florida International University, Miami, Florida
| |
Collapse
|
25
|
Strömberg U, Peterson S, Holmberg E, Holmén A, Persson B, Sandberg C, Nilbert M. Cutaneous malignant melanoma show geographic and socioeconomic disparities in stage at diagnosis and excess mortality. Acta Oncol 2016; 55:993-1000. [PMID: 26935355 DOI: 10.3109/0284186x.2016.1144934] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 01/15/2016] [Accepted: 01/17/2016] [Indexed: 01/18/2023]
Abstract
Background Preventive measures are needed to counteract the increasing burden of cutaneous malignant melanoma (CMM). As a basis for rational melanoma prevention, we investigated geographic differences and impact from socioeconomic factors related to incidence, clinical stage at diagnosis and outcome. Material and methods All patients with primary invasive CMM diagnosed in 2004-2013 in the southern and the western Swedish health care regions with a population of 2.9 million adults were eligible for the study. Population-based data were obtained from the national Cancer Register and the national Melanoma Quality Register. Geographic and socioeconomic differences in incidence per stage at diagnosis were mapped and correlated to excess mortality. Results Disease mapping based on 9743 cases in 99 municipalities and 20 metropolitan districts showed marked, regional disparities in stage-specific incidence of CMM. The incidence of stage I-II tumors was higher in the western health care region, whereas the incidence of stage III-IV CMMs was higher in the southern region. The divergent incidence patterns per stage at diagnosis were consistent across population strata based on educational level. The geographic disparities in CMM stage influenced relative survival with an excess five-year mortality ratio in the southern region versus the western region of 1.49 (95% confidence interval 1.22-1.82). The excess mortality ratio for patients with low versus high educational level was 1.81 (1.37-2.40). Conclusion Residential region and educational level influenced CMM stage and, thereby, excess mortality. These observations suggest that geographic as well as socioeconomic data should be considered in prevention of CMM.
Collapse
Affiliation(s)
- Ulf Strömberg
- a Institute of Clinical Sciences, Division of Cancer Epidemiology , Lund University , Lund, Sweden
- b Department of Research, Development and Education , Sahlgrenska University Hospital , Gothenburg , Sweden
| | | | - Erik Holmberg
- d Regional Cancer Center West , Gothenburg , Sweden
- e Institute of Clinical Sciences, Department of Oncology , Sahlgrenska Academy at University of Gothenburg , Gothenburg , Sweden
| | - Anders Holmén
- b Department of Research, Development and Education , Sahlgrenska University Hospital , Gothenburg , Sweden
| | - Bertil Persson
- c Regional Cancer Center South , Lund , Sweden
- f Department of Dermatology , Skane University Hospital , Lund , Sweden
| | - Carin Sandberg
- d Regional Cancer Center West , Gothenburg , Sweden
- g Department of Dermatology , Sahlgrenska University Hospital , Gothenburg , Sweden
| | - Mef Nilbert
- c Regional Cancer Center South , Lund , Sweden
- h Institute of Clinical Sciences, Division of Oncology and Pathology , Lund University , Lund , Sweden
- i Clinical Research Centre, Hvidovre Hospital, Copenhagen University , Copenhagen , Denmark
| |
Collapse
|
26
|
Mintsoulis D, Beecker J. Digital Dermoscopy Photographs Outperform Handheld Dermoscopy in Melanoma Diagnosis. J Cutan Med Surg 2016; 20:602-605. [DOI: 10.1177/1203475416653720] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background: Pigmented lesion clinics (PLCs) that use technology such as digital dermoscopy and total-body photography are thought to confer a clinical advantage for patients at high risk of developing melanoma over general dermatology clinics (GDCs) with regular dermoscopy. Objective: To examine the difference between depths of melanomas diagnosed in a PLC and a GDC. Methods: Medical records from 257 patients at the PLC at The Ottawa Hospital and 441 patients from a GDC were reviewed. Results: Invasive melanoma was less frequent than in situ melanoma at the PLC (7.14% vs 38.27%; P = .02). The average Breslow depth for melanomas at the PLC was also smaller compared with the GDC (0.0371 vs 0.3450 mm; P = .02). Conclusions: The use of digital dermoscopy and total-body photography together in a PLC appears to be an effective way to monitor patients at high risk of melanoma.
Collapse
Affiliation(s)
| | - Jennifer Beecker
- Division of Dermatology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada
| |
Collapse
|
27
|
Srisuttiyakorn C, Bulloch K, Rodic N, Bosenberg M, Ariyan S, Narayan D, Gould Rothberg BE, Galan A. Intratumoral multinucleated giant cells are not a prognostic pathologic feature in cutaneous melanoma. J Cutan Pathol 2016; 43:821-9. [DOI: 10.1111/cup.12750] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 05/30/2016] [Accepted: 05/30/2016] [Indexed: 11/30/2022]
Affiliation(s)
- Chutika Srisuttiyakorn
- Department of Medicine, Division of DermatologyPhramongkutklao Hospital Bangkok Thailand
- Department of DermatologyYale School of Medicine New Haven CT USA
| | - Kaleigh Bulloch
- Department of Internal Medicine, Medical Oncology DivisionYale School of Medicine New Haven CT USA
| | - Nemanja Rodic
- Department of DermatologyYale School of Medicine New Haven CT USA
| | - Marcus Bosenberg
- Department of DermatologyYale School of Medicine New Haven CT USA
- Department of PathologyYale School of Medicine New Haven CT USA
| | - Stephen Ariyan
- Department of Surgery, Section of Plastic and Reconstructive SurgeryYale School of Medicine New Haven CT USA
| | - Deepak Narayan
- Department of Surgery, Section of Plastic and Reconstructive SurgeryYale School of Medicine New Haven CT USA
| | - Bonnie E. Gould Rothberg
- Department of Internal Medicine, Medical Oncology DivisionYale School of Medicine New Haven CT USA
- Department of PathologyYale School of Medicine New Haven CT USA
- Department of EpidemiologyYale School of Medicine New Haven CT USA
| | - Anjela Galan
- Department of DermatologyYale School of Medicine New Haven CT USA
- Department of PathologyYale School of Medicine New Haven CT USA
| |
Collapse
|
28
|
Ruiz de Luzuriaga AM, Mhlaba J, Roman C. Primary Care of Adult Women. Obstet Gynecol Clin North Am 2016; 43:181-200. [DOI: 10.1016/j.ogc.2016.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Bruno W, Pastorino L, Ghiorzo P, Andreotti V, Martinuzzi C, Menin C, Elefanti L, Stagni C, Vecchiato A, Rodolfo M, Maurichi A, Manoukian S, De Giorgi V, Savarese I, Gensini F, Borgognoni L, Testori A, Spadola G, Mandalà M, Imberti G, Savoia P, Astrua C, Ronco AM, Farnetti A, Tibiletti MG, Lombardo M, Palmieri G, Ayala F, Ascierto P, Ghigliotti G, Muggianu M, Spagnolo F, Picasso V, Tanda ET, Queirolo P, Bianchi-Scarrà G. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. J Am Acad Dermatol 2016; 74:325-32. [PMID: 26775776 DOI: 10.1016/j.jaad.2015.09.053] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2015] [Revised: 09/24/2015] [Accepted: 09/29/2015] [Indexed: 12/20/2022]
Abstract
BACKGROUND Multiple primary melanoma (MPM), in concert with a positive family history, is a predictor of cyclin-dependent kinase (CDK) inhibitor 2A (CDKN2A) germline mutations. A rule regarding the presence of either 2 or 3 or more cancer events (melanoma and pancreatic cancer) in low or high melanoma incidence populations, respectively, has been established to select patients for genetic referral. OBJECTIVE We sought to determine the CDKN2A/CDK4/microphthalmia-associated transcription factor mutation rate among Italian patients with MPM to appropriately direct genetic counseling regardless of family history. METHODS In all, 587 patients with MPM and an equal number with single primary melanomas and control subjects were consecutively enrolled at the participating centers and tested for CDKN2A, CDK4, and microphthalmia-associated transcription factor. RESULTS CDKN2A germline mutations were found in 19% of patients with MPM versus 4.4% of patients with single primary melanoma. In familial MPM cases the mutation rate varied from 36.6% to 58.8%, whereas in sporadic MPM cases it varied from 8.2% to 17.6% in patients with 2 and 3 or more melanomas, respectively. The microphthalmia-associated transcription factor E318K mutation accounted for 3% of MPM cases altogether. LIMITATIONS The study was hospital based, not population based. Rare novel susceptibility genes were not tested. CONCLUSION Italian patients who developed 2 melanomas, even in situ, should be referred for genetic counseling even in the absence of family history.
Collapse
Affiliation(s)
- William Bruno
- Department of Internal Medicine, Medical Specialties and Surgical Science and Integrated Diagnostics, University of Genoa, Genoa, Italy; Genetics of Rare Cancers, IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - Lorenza Pastorino
- Department of Internal Medicine, Medical Specialties and Surgical Science and Integrated Diagnostics, University of Genoa, Genoa, Italy; Genetics of Rare Cancers, IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
| | - Paola Ghiorzo
- Department of Internal Medicine, Medical Specialties and Surgical Science and Integrated Diagnostics, University of Genoa, Genoa, Italy; Genetics of Rare Cancers, IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - Virginia Andreotti
- Department of Internal Medicine, Medical Specialties and Surgical Science and Integrated Diagnostics, University of Genoa, Genoa, Italy
| | - Claudia Martinuzzi
- Department of Internal Medicine, Medical Specialties and Surgical Science and Integrated Diagnostics, University of Genoa, Genoa, Italy; Department of Internal Medicine, Medical Specialties and Surgical Science and Integrated Diagnostics, University of Genoa, Genoa, Italy
| | - Chiara Menin
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, Istituto Oncologico Veneto (IOV)-IRCCS, Padua, Italy
| | - Lisa Elefanti
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, Istituto Oncologico Veneto (IOV)-IRCCS, Padua, Italy
| | - Camilla Stagni
- Section of Oncology and Immunology, Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy
| | - Antonella Vecchiato
- Melanoma and Soft Tissue Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Monica Rodolfo
- Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - Andrea Maurichi
- Melanoma and Sarcoma Surgery Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - Siranoush Manoukian
- Medical Genetics Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | | | - Imma Savarese
- Department of Dermatology, University of Florence, Florence, Italy
| | - Francesca Gensini
- Unit of Medical Genetics, Department of Biomedical Experimental and Clinical Sciences, University of Florence, Florence, Italy
| | - Lorenzo Borgognoni
- Plastic Surgery Unit, Regional Melanoma Referral Center, Santa Maria Annunziata Hospital, Florence, Italy
| | - Alessandro Testori
- Division of Dermatoncological Surgery, European Institute of Oncology, Milan, Italy
| | - Giuseppe Spadola
- Division of Dermatoncological Surgery, European Institute of Oncology, Milan, Italy
| | - Mario Mandalà
- Medical Oncology Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | | | - Paola Savoia
- Department of Medical Sciences, Dermatology Section, University of Turin, Turin, Italy
| | - Chiara Astrua
- Department of Medical Sciences, Dermatology Section, University of Turin, Turin, Italy
| | - Anna Maria Ronco
- Dermatoncological Surgery Unit, Presidio Sanitario Gradenigo, Turin, Italy
| | | | | | | | - Giuseppe Palmieri
- Cancer Genetics Unit, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy
| | - Fabrizio Ayala
- Department of Melanoma, National Cancer Institute Pascale Foundation, Naples, Italy
| | - Paolo Ascierto
- Department of Melanoma, National Cancer Institute Pascale Foundation, Naples, Italy
| | - Giovanni Ghigliotti
- Dermatology Unit, IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - Marisa Muggianu
- Department of Plastic and Reconstructive Surgery, IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - Francesco Spagnolo
- Department of Plastic and Reconstructive Surgery, IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - Virginia Picasso
- Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera Universitaria (AOU) San Martino-Istituto Nazionale dei Tumori (IST) Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - Enrica Teresa Tanda
- Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera Universitaria (AOU) San Martino-Istituto Nazionale dei Tumori (IST) Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - Paola Queirolo
- Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera Universitaria (AOU) San Martino-Istituto Nazionale dei Tumori (IST) Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - Giovanna Bianchi-Scarrà
- Department of Internal Medicine, Medical Specialties and Surgical Science and Integrated Diagnostics, University of Genoa, Genoa, Italy; Genetics of Rare Cancers, IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| |
Collapse
|
30
|
Schiffman JD, Breen M. Comparative oncology: what dogs and other species can teach us about humans with cancer. Philos Trans R Soc Lond B Biol Sci 2016; 370:rstb.2014.0231. [PMID: 26056372 DOI: 10.1098/rstb.2014.0231] [Citation(s) in RCA: 237] [Impact Index Per Article: 29.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Over 1.66 million humans (approx. 500/100,000 population rate) and over 4.2 million dogs (approx. 5300/100,000 population rate) are diagnosed with cancer annually in the USA. The interdisciplinary field of comparative oncology offers a unique and strong opportunity to learn more about universal cancer risk and development through epidemiology, genetic and genomic investigations. Working across species, researchers from human and veterinary medicine can combine scientific findings to understand more quickly the origins of cancer and translate these findings to novel therapies to benefit both human and animals. This review begins with the genetic origins of canines and their advantage in cancer research. We next focus on recent findings in comparative oncology related to inherited, or genetic, risk for tumour development. We then detail the somatic, or genomic, changes within tumours and the similarities between species. The shared cancers between humans and dogs that we discuss include sarcoma (osteosarcoma, soft tissue sarcoma, histiocytic sarcoma, hemangiosarcoma), haematological malignancies (lymphoma, leukaemia), bladder cancer, intracranial neoplasms (meningioma, glioma) and melanoma. Tumour risk in other animal species is also briefly discussed. As the field of genomics advances, we predict that comparative oncology will continue to benefit both humans and the animals that live among us.
Collapse
Affiliation(s)
- Joshua D Schiffman
- Department of Pediatrics and Oncological Sciences, Primary Children's Hospital, Intermountain Healthcare, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
| | - Matthew Breen
- Department of Molecular Biomedical Sciences, College of Veterinary Medicine, Center for Comparative Medicine and Translational Research, Center for Human Health and the Environment, Cancer Genetics, UNC Lineberger Comprehensive Cancer Center, North Carolina State University, Raleigh, NC, USA
| |
Collapse
|
31
|
Affiliation(s)
- Franki Lambert Smith
- Department of Dermatology, University of Colorado School of Medicine, Aurora, Colorado
| | - Joshua Wisell
- Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado
| | - Mariah Brown
- Department of Dermatology, University of Colorado School of Medicine, Aurora, Colorado
| |
Collapse
|
32
|
Acral melanocytic lesions in the United States: Prevalence, awareness, and dermoscopic patterns in skin-of-color and non-Hispanic white patients. J Am Acad Dermatol 2016; 74:724-30.e1. [DOI: 10.1016/j.jaad.2015.11.035] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2015] [Revised: 11/23/2015] [Accepted: 11/30/2015] [Indexed: 11/18/2022]
|
33
|
Tellez A, Rueda S, Conic RZ, Powers K, Galdyn I, Mesinkovska NA, Gastman B. Risk factors and outcomes of cutaneous melanoma in women less than 50 years of age. J Am Acad Dermatol 2016; 74:731-8. [PMID: 26803345 DOI: 10.1016/j.jaad.2015.11.014] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Revised: 11/08/2015] [Accepted: 11/12/2015] [Indexed: 01/23/2023]
Abstract
BACKGROUND Melanoma is the fifth most common cancer in the United States, with recent reports indicating increasing incidence among young women. OBJECTIVE This study sought to investigate histopathology, staging, risk factors, and outcomes of cutaneous melanoma in women younger than 50 years. METHODS All female patients aged up to 49 years with biopsy-proven diagnosis of melanoma between 1988 and 2012 were included. Patients with a follow-up of less than 2 years were excluded. RESULTS A total of 462 patients were identified, with mean age of 34.7 years. Invasive melanoma was less common in women 19 years of age or younger (P < .0008). Positive sentinel node status (P < .008), recurrence rates, metastatic disease (P < .001), and death rates (P < .008) were higher for women ages 40 to 49 years. The 41 patients with a pregnancy-associated melanoma had a significantly worse prognosis in comparison with a control group of nonpregnant patients, with a 9-fold increase in recurrence (P < .001), 7-fold increase in metastasis (P = .03) and 5-fold increase in mortality (P = .06). LIMITATIONS This was a retrospective study. CONCLUSION The increasing incidence of melanoma for women younger than 50 years suggests that regular skin checks and self-examinations are warranted. In addition, in women given the diagnosis of melanoma during or within 1 year after childbirth, regular follow-up and monitoring for recurrence are recommended.
Collapse
Affiliation(s)
| | - Steven Rueda
- Department of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio
| | - Ruzica Z Conic
- Department of Dermatology, Cleveland Clinic, Cleveland, Ohio
| | - Kristin Powers
- Georgetown University School of Medicine, Washington, District of Columbia
| | - Izabela Galdyn
- Department of Plastic Surgery, Loma Linda University, Loma Linda, California
| | | | - Brian Gastman
- Department of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio.
| |
Collapse
|
34
|
Lai YW, Wang SW, Chang CH, Liu SC, Chen YJ, Chi CW, Chiu LP, Chen SS, Chiu AW, Chung CH. Butein inhibits metastatic behavior in mouse melanoma cells through VEGF expression and translation-dependent signaling pathway regulation. Altern Ther Health Med 2015; 15:445. [PMID: 26694191 PMCID: PMC4687249 DOI: 10.1186/s12906-015-0970-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2015] [Accepted: 12/14/2015] [Indexed: 12/31/2022]
Abstract
Background Melanoma is an aggressive skin cancer and a predominant cause of skin cancer-related deaths. A previous study has demonstrated the ability of butein to inhibit tumor proliferation and invasion. However, the anti-metastatic mechanisms and in vivo effects of butein have not been fully elucidated. Methods MTT cell viability assays were used to evaluate the antitumor effects of butein in vitro. Cytotoxic effects of butein were measured by lactate dehydrogenase assay. Anti-migratory effects of butein were evaluated by two-dimensional scratch and transwell migration assays. Signaling transduction and VEGF-releasing assays were measured by Western blotting and ELISA. We also conducted an experimental analysis of the metastatic potential of tumor cells injected into the tail vein of C57BL/6 mice. Results We first demonstrated the effect of butein on cell viability at non-cytotoxic concentrations (1, 3, and 10 μM). In vitro, butein was found to inhibit the migration of B16F10 cells in a concentration-dependent manner using transwell and scratch assays. Butein had a dose-dependent effect on focal adhesion kinase, Akt, and ERK phosphorylation in B16F10 cells. Butein efficiently inhibited the mTOR/p70S6K translational inhibition machinery and decreased the production of VEGF in B16F10 cells. Furthermore, the in vivo antitumor effects of butein were demonstrated using a pulmonary metastasis model. Conclusion The results of the present study indicate the potential utility of butein in the treatment of melanoma.
Collapse
|
35
|
Al-Dujaili Z, Henry M, Dorizas AS, Sadick NS. Skin cancer concerns particular to women. Int J Womens Dermatol 2015; 1:123-125. [PMID: 28491974 PMCID: PMC5418873 DOI: 10.1016/j.ijwd.2015.07.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Revised: 07/16/2015] [Accepted: 07/16/2015] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Skin cancer has reached epidemic proportions, with more new cases diagnosed annually than the combined incidence of cancers of the breast, prostate, lung, and colon. Estimates show 2 to 3 million new cases of non-melanoma skin cancer (NMSC) every year, and, among women, it is the young (younger than 45 years) who are disproportionately affected. OBJECTIVE This article aims to address questions and concerns pertinent to skin cancer in a woman-centric way. An updated landscape of causative factors, the latest detection/treatment methods, and ultimately the preventative measures available to them are described. METHODS A broad literature search was conducted using the PubMed database with search terms focusing on female gender. Additional articles were identified from cited references. CONCLUSIONS The published findings on causation of melanoma skin cancer and non-melanoma skin cancer in females are outlined, as well as current detection methods and treatment options. Furthermore, a variety of preventative measures specific to women that can reduce the chance of being diagnosed with skin cancer are discussed.
Collapse
Affiliation(s)
- Z Al-Dujaili
- Sadick Dermatology, New York, NY.,New York-Presbyterian Hospital, New York, NY
| | - M Henry
- Sadick Dermatology, New York, NY.,Department of Dermatology, Weill Cornell Medical College, New York, NY
| | - A S Dorizas
- Department of Dermatology, University at Buffalo, NY
| | - N S Sadick
- Sadick Dermatology, New York, NY.,Department of Dermatology, Weill Cornell Medical College, New York, NY
| |
Collapse
|
36
|
Walter FM, Abel GA, Lyratzopoulos G, Melia J, Greenberg D, Brewster DH, Butler H, Corrie PG, Campbell C. Seasonal variation in diagnosis of invasive cutaneous melanoma in Eastern England and Scotland. Cancer Epidemiol 2015; 39:554-61. [PMID: 26141681 PMCID: PMC4542219 DOI: 10.1016/j.canep.2015.06.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Revised: 06/20/2015] [Accepted: 06/22/2015] [Indexed: 11/20/2022]
Abstract
BACKGROUND Worldwide, the incidence of cutaneous melanoma has been reported to be highest in the summer and lowest in the winter. Northern Irish data suggested seasonal variation for women only, especially those with thinner melanomas, sited on limbs. We interrogated two larger UK cancer registries for temporal differences in melanoma diagnosis and associated patient characteristics. METHODS Melanomas diagnosed from 2006 to 2010 in the Eastern England and Scottish cancer registries (n=11,611) were analysed by month of diagnosis, patient demographics and melanoma characteristics, using descriptive and multivariate modelling methods. RESULTS More patients with melanoma were diagnosed in the summer months (June 9.9%, July 9.7%, August 9.8%) than the winter months (December 7.2%, January 7.2%, February 7.1%) and this pattern was consistent in both regions. There was evidence that the seasonal patterns varied by sex (p=0.015), melanoma thickness (p=0.002), body site (p=0.006), and type (superficial spreading melanomas p=0.005). The seasonal variation was greatest for diagnosis of melanomas occurring on the limbs. CONCLUSION This study has confirmed seasonal variation in melanoma diagnosis in Eastern England and Scotland across almost all population demographics and melanoma characteristics studied, with higher numbers diagnosed in the summer months, particularly on the limbs. Seasonal patterns in skin awareness and related help-seeking are likely to be implicated. Targeted patient interventions to increase sun awareness and encourage year-long skin inspection are warranted.
Collapse
Affiliation(s)
- Fiona M Walter
- Department of Public Health & Primary Care, University of Cambridge, UK.
| | - Gary A Abel
- Department of Public Health & Primary Care, University of Cambridge, UK
| | - Georgios Lyratzopoulos
- Department of Public Health & Primary Care, University of Cambridge, UK; Health Behaviour Research Centre, University College London, UK
| | - Jane Melia
- Department of Public Health & Primary Care, University of Cambridge, UK
| | - David Greenberg
- Eastern Cancer Registry and Information Centre, Cambridge, UK; Department of Public Health & Primary Care, University of Cambridge, UK
| | - David H Brewster
- Scottish Cancer Registry, NHS National Services Scotland, Edinburgh, UK; University of Edinburgh, UK
| | - Helen Butler
- Department of Public Health & Primary Care, University of Cambridge, UK
| | - Pippa G Corrie
- Cambridge University Hospitals NHS Foundation Trust (Addenbrooke's Hospital), UK
| | | |
Collapse
|
37
|
Mitochondrial DNA copy number in peripheral blood and melanoma risk. PLoS One 2015; 10:e0131649. [PMID: 26110424 PMCID: PMC4482392 DOI: 10.1371/journal.pone.0131649] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Accepted: 06/05/2015] [Indexed: 02/07/2023] Open
Abstract
Mitochondrial DNA (mtDNA) copy number in peripheral blood has been suggested as risk modifier in various types of cancer. However, its influence on melanoma risk is unclear. We evaluated the association between mtDNA copy number in peripheral blood and melanoma risk in 500 melanoma cases and 500 healthy controls from an ongoing melanoma study. The mtDNA copy number was measured using real-time polymerase chain reaction. Overall, mean mtDNA copy number was significantly higher in cases than in controls (1.15 vs 0.99, P<0.001). Increased mtDNA copy number was associated with a 1.45-fold increased risk of melanoma (95% confidence interval: 1.12-1.97). Significant joint effects between mtDNA copy number and variables related to pigmentation and history of sunlight exposure were observed. This study supports an association between increased mtDNA copy number and melanoma risk that is independent on the known melanoma risk factors (pigmentation and history of sunlight exposure).
Collapse
|
38
|
Daniel CL, Armstrong GT, Keske RR, Davine JA, McDonald AJ, Sprunck-Harrild KM, Coleman C, Haneuse SJ, Mertens AC, Emmons KM, Marghoob AA, Elkin EB, Dusza SW, Robison LL, Geller AC. Advancing Survivors' Knowledge (ASK) about skin cancer study: study protocol for a randomized controlled trial. Trials 2015; 16:109. [PMID: 25873142 PMCID: PMC4392639 DOI: 10.1186/s13063-015-0637-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2014] [Accepted: 03/05/2015] [Indexed: 11/15/2022] Open
Abstract
Background Advances in treatment have increased childhood cancer 5-year survival rates to greater than 80%. However, children previously treated with radiation are at significantly increased risk of developing subsequent neoplasms, the most common of which are skin cancers. The National Cancer Institute and Children’s Oncology Group have issued recommendations for survivors treated with radiation to perform monthly skin self-examinations and receive a physician skin examination at least annually, as early detection has demonstrated markedly improved outcomes in the diagnosis and treatment of skin cancers. The goal of the present study is to increase rates of skin self-examinations and clinical skin examinations among adult survivors of childhood cancer treated with radiation. Methods/Design This randomized controlled trial uses a 3-group comparative effectiveness design comparing: (1) Patient Activation and Education (PAE) including text messaging, print and web-based tutorials over 12 months; (2) PAE plus physician activation (PAE + MD) adding physician activation/educational materials about survivors’ increased skin cancer risk and conducting full-body skin exams; and (3) PAE plus physician activation, plus teledermoscopy (PAE + MD + TD) adding participant receipt of a dermatoscope intended to empower them to photograph suspect moles or lesions for review by the study dermatologist. Discussion The current study addresses barriers to screening in this population by providing educational and motivational information for both survivors and physicians regarding the value of periodic skin examinations. It also utilizes innovative mobile health technology to encourage and motivate (that is activate) survivors to conduct skin self-examinations, request physician exams, and obtain treatment when worrisome lesions are found. Finally, as a comparative effectiveness trial, this study isolates the effects of adding specific components to the patient activation intervention to test the most effective intervention for enhancing skin examination vigilance among this high-risk group. Trial registration Clinicaltrials.gov: NCT02046811; Registration date: 22 January 2014.
Collapse
Affiliation(s)
- Casey L Daniel
- Department of Social and Behavioral Sciences, Harvard TH Chan School of Public Health, 677 Huntington Avenue, Kresge 718, 02115-6028, Boston, MA, USA.
| | - Gregory T Armstrong
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 735, 38105-3678, Memphis, TN, USA.
| | - Robyn R Keske
- Department of Social and Behavioral Sciences, Harvard TH Chan School of Public Health, 677 Huntington Avenue, Kresge 718, 02115-6028, Boston, MA, USA.
| | - Jessica A Davine
- Department of Social and Behavioral Sciences, Harvard TH Chan School of Public Health, 677 Huntington Avenue, Kresge 718, 02115-6028, Boston, MA, USA.
| | - Aaron J McDonald
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 735, 38105-3678, Memphis, TN, USA.
| | - Kim M Sprunck-Harrild
- Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, LW601, 02215-5450, Boston, MA, USA.
| | - Catherine Coleman
- Department of Population Sciences, Dana-Farber Cancer Institute, 450 Brookline Avenue, 02215-5450, Boston, MA, USA.
| | - Sebastien J Haneuse
- Department of Biostatistics, Harvard TH Chan School of Public Health, 655 Huntington Avenue, Bldg 2, Rm 451, 02115-6009, Boston, MA, USA.
| | - Ann C Mertens
- Department of Pediatrics, Emory University, Emory Children's Center, 2015 Uppergate Drive, 4th floor, 30322-1014, Atlanta, GA, USA.
| | - Karen M Emmons
- Kaiser Permanente, 1800 Harrison Street, 16th Floor, #161R03, 94612-3463, Oakland, CA, USA.
| | - Ashfaq A Marghoob
- Memorial-Sloan Kettering Cancer Center, 1275 York Ave, 10065-6007, New York, NY, USA.
| | - Elena B Elkin
- Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 44, 10065-6007, New York, NY, USA.
| | - Stephen W Dusza
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, 160 East 53rd St, 2nd Floor, 10022-5243, New York, NY, USA.
| | - Leslie L Robison
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 735, 38105-3678, Memphis, TN, USA.
| | - Alan C Geller
- Department of Social and Behavioral Sciences, Harvard TH Chan School of Public Health, 677 Huntington Avenue, Kresge 718, 02115-6028, Boston, MA, USA.
| |
Collapse
|
39
|
Winkelmann RR, Rigel DS. Response to CME article "Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions. Part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology". J Am Acad Dermatol 2015; 72:745-7. [PMID: 25773423 DOI: 10.1016/j.jaad.2014.11.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Accepted: 11/24/2014] [Indexed: 10/23/2022]
Affiliation(s)
| | - Darrell S Rigel
- Department of Dermatology, New York University School of Medicine, New York, New York
| |
Collapse
|
40
|
Alegre E, Sammamed M, Fernández-Landázuri S, Zubiri L, González Á. Circulating biomarkers in malignant melanoma. Adv Clin Chem 2015; 69:47-89. [PMID: 25934359 DOI: 10.1016/bs.acc.2014.12.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Melanoma is an aggressive tumor with increasing incidence worldwide. Biomarkers are valuable tools to minimize the cost and improve efficacy of treatment of this deadly disease. Serological markers have not widely been introduced in routine clinical practice due to their insufficient diagnostic sensitivity and specificity. It is likely that the lack of objective responses with traditional treatment hinder biomarker research and development in melanoma. Recently, new drugs and therapies have, however, emerged in advanced melanoma with noticeable objective response ratio and survival. In this new scenario, serological tumor markers should be revisited. In addition, other potential circulating biomarkers such as cell-free DNA, exosomes, microRNA, and circulating tumor cells have also been identified. In this review, we summarize classical and emerging tumor markers and discuss their possible roles in emerging therapeutics.
Collapse
Affiliation(s)
- Estibaliz Alegre
- Laboratory of Biochemistry, University Clinic of Navarra, Pamplona, Spain
| | - Miguel Sammamed
- Centro de Investigación Médica Aplicada (CIMA), University of Navarra, Pamplona, Spain; Department of Oncology, University Clinic of Navarra, Pamplona, Spain
| | | | - Leyre Zubiri
- Department of Oncology, University Clinic of Navarra, Pamplona, Spain
| | - Álvaro González
- Laboratory of Biochemistry, University Clinic of Navarra, Pamplona, Spain.
| |
Collapse
|
41
|
Lei X, Guan CW, Song Y, Wang H. The multifaceted role of CD146/MCAM in the promotion of melanoma progression. Cancer Cell Int 2015; 15:3. [PMID: 25685061 PMCID: PMC4326486 DOI: 10.1186/s12935-014-0147-z] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2014] [Accepted: 12/17/2014] [Indexed: 12/14/2022] Open
Abstract
Human malignant melanoma is a common primary malignant cutaneous tumour derived from transformed epidermal melanocytes. Patients with melanoma have a high rate of mortality due to resistance to chemotherapeutic drugs, a major obstacle to a successful treatment. Several reports have suggested that CD146 plays an important role as a signalling molecule in human melanoma. This role includes CD146 as a participant in inflammation, differentiation, adhesion, tumourigenicity, metastasis, invasion and angiogenesis among other processes, which suggests that this molecule promotes the progression of human melanoma as a multifaceted regulator. In this article, we explore the effects and corresponding mechanisms with respect to the role of CD146/MUC18 in the promotion of human melanoma progression. Collectively, the studies indicated that targeting CD146, because it is a suitable marker of poor patient outcome, might be useful in the design of future strategies for the prevention and treatment of human melanoma.
Collapse
Affiliation(s)
- Xing Lei
- Department of Orthopedic Surgery, Linyi People's Hospital, Linyi, 276000 China
| | - Ce-Wen Guan
- Department of Orthopedic Surgery, the First Affiliated Hospital, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001 China
| | - Yang Song
- Department of Orthopedic Surgery, the Second Affiliated Hospital, Harbin Medical University, Harbin, 150001 China
| | - Huan Wang
- Department of Orthopedic Surgery, the First Affiliated Hospital, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001 China
| |
Collapse
|